Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

Only vaccinating the placebo group would be much easier once the US FDA grants an EUA for its coronavirus vaccine, Pfizer says.

A crossover design could allow for more long-term safety and efficacy follow-up.

A crossover design to maintain the placebo controls for its coronavirus vaccine trial may be too complicated and labor-intensive for Pfizer Inc..

The company and partner BioNTech SE, have requested an emergency use authorization to use the vaccine in adults age...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers